Labetalol infusion for refractory hypertension causing severe hypotension and bradycardia: an issue of patient safety, Patient Safety in Surgery

Por um escritor misterioso
Last updated 31 março 2025
Labetalol infusion for refractory hypertension causing severe hypotension  and bradycardia: an issue of patient safety, Patient Safety in Surgery
Incremental doses of intravenous labetalol are safe and effective and, at times, such therapy may need to be augmented by a continuous infusion of labetalol to control severe hypertension. Continuous infusions of labetalol may exceed the recommended maximum daily dose of 300 mg on occasion. We report a case in which hypertension occurring after an abdominal aortic aneurysm repair, initially responsive to intermittent intravenous beta-blockade, became resistant to this therapy leading to the choice of an intravenous labetalol infusion as the therapeutic option. The labetalol infusion resulted in a profound cardiovascular compromise in this postoperative critically ill patient. While infusions of labetalol have successfully been used, prolonged administration in the intensive care unit requires vigilance and the establishment of a therapeutic rationale/policy for interventions, such as the ready availability of glucagon, β-agonists, phosphodiesterase inhibitors, insulin, and vasopressin when severe cardiovascular depression occurs.
Labetalol infusion for refractory hypertension causing severe hypotension  and bradycardia: an issue of patient safety, Patient Safety in Surgery
Effectiveness and Safety of Nicardipine and Labetalol Infusion for Blood Pressure Management in Patients with Intracerebral and Subarachnoid Hemorrhage
Labetalol infusion for refractory hypertension causing severe hypotension  and bradycardia: an issue of patient safety, Patient Safety in Surgery
LABETALOL HYDROCHLORIDE INJECTION, USP
Labetalol infusion for refractory hypertension causing severe hypotension  and bradycardia: an issue of patient safety, Patient Safety in Surgery
Full article: Remifentanil versus labetalol for deliberate hypotensive anesthesia in children undergoing cochlear implantation: A randomized clinical trial
Labetalol infusion for refractory hypertension causing severe hypotension  and bradycardia: an issue of patient safety, Patient Safety in Surgery
Part 12: Cardiac Arrest in Special Situations
Labetalol infusion for refractory hypertension causing severe hypotension  and bradycardia: an issue of patient safety, Patient Safety in Surgery
Hemodynamic Safety of Continuous Infusion Labetalol Versus Esmolol Combination Therapies for Type B Aortic Dissections
Labetalol infusion for refractory hypertension causing severe hypotension  and bradycardia: an issue of patient safety, Patient Safety in Surgery
Hypertension (Chapter 3) - Post-Anesthesia Care
Labetalol infusion for refractory hypertension causing severe hypotension  and bradycardia: an issue of patient safety, Patient Safety in Surgery
Acute Severe Hypertension
Labetalol infusion for refractory hypertension causing severe hypotension  and bradycardia: an issue of patient safety, Patient Safety in Surgery
Frontiers Management of Blood Pressure During and After Recanalization Therapy for Acute Ischemic Stroke
Labetalol infusion for refractory hypertension causing severe hypotension  and bradycardia: an issue of patient safety, Patient Safety in Surgery
Management of Women With Acquired Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 3/5 - ScienceDirect
Labetalol infusion for refractory hypertension causing severe hypotension  and bradycardia: an issue of patient safety, Patient Safety in Surgery
Hypertensive emergency - EMCrit Project
Labetalol infusion for refractory hypertension causing severe hypotension  and bradycardia: an issue of patient safety, Patient Safety in Surgery
Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial - ScienceDirect

© 2014-2025 praharacademy.in. All rights reserved.